We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

144 hedge funds and large institutions have $946M invested in Protagonist Therapeutics in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 65 increasing their positions, 40 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

970% more call options, than puts

Call options by funds: $12.2M | Put options by funds: $1.14M

63% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 40

0.52% less ownership

Funds ownership: 99.1% → 98.58% (-0.52%)

14% less funds holding

Funds holding: 167 → 144 (-23)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

40% less capital invested

Capital invested by funds: $1.57B → $946M (-$621M)

58% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 40

Holders
144
Holders Change
-23
Holders Change %
-13.77%
% of All Funds
2.29%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
17
Increased
65
Reduced
40
Closed
40
Calls
$12.2M
Puts
$1.14M
Net Calls
+$11.1M
Net Calls Change
-$15.7M

Top Buyers

1
BI
BVF Inc
California
+$38.2M
2
B
Braidwell
Connecticut
+$21.5M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$21.5M
4
FCM
Farallon Capital Management
California
+$18.1M
5
KCM
Kynam Capital Management
New Jersey
+$16.4M

Top Sellers

1
CAM
Cormorant Asset Management
Massachusetts
-$41.4M
2
Holocene Advisors
Holocene Advisors
New York
-$22.2M
3
Deutsche Bank
Deutsche Bank
Germany
-$15.3M
4
AG
Artal Group
Luxembourg
-$13.8M
5
WP
Woodline Partners
California
-$11.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$95.8M +$38.2M +1,968,948 +52%
FCM
2
Farallon Capital Management
California
$90.8M +$18.1M +935,000 +21%
RI
3
RTW Investments
New York
$90.3M – – –
BlackRock
4
BlackRock
New York
$87.2M +$4.27M +220,152 +4%
State Street
5
State Street
Massachusetts
$65.8M +$7.57M +390,152 +11%
Vanguard Group
6
Vanguard Group
Pennsylvania
$53.8M +$1.56M +80,639 +3%
JJ
7
Johnson & Johnson
New Jersey
$40.9M – – –
KCM
8
Kynam Capital Management
New Jersey
$30.3M +$16.4M +843,359 +86%
CAC
9
Cowen and Company
New York
$27.6M – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$19.7M +$2.02M +104,072 +10%
B
11
Braidwell
Connecticut
$18.5M +$21.5M +1,109,150 New
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$18.5M +$21.5M +1,108,140 New
PA
13
Perceptive Advisors
New York
$17.6M -$8.06M -415,488 -28%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$15.7M -$1.9M -97,831 -9%
JFG
15
Jefferies Financial Group
New York
$13.9M +$1.46M +75,000 +10%
T. Rowe Price Associates
16
T. Rowe Price Associates
Maryland
$13.9M +$5.82K +300 +0%
6CM
17
683 Capital Management
New York
$12.2M -$1.58M -81,216 -10%
Adage Capital Partners
18
Adage Capital Partners
Massachusetts
$11.7M -$11.5M -592,711 -46%
CS
19
Candriam SCA
Luxembourg
$10.5M -$1.84M -95,000 -13%
Northern Trust
20
Northern Trust
Illinois
$9.39M +$477K +24,563 +5%
HSBC Holdings
21
HSBC Holdings
United Kingdom
$9.17M -$119K -6,150 -1%
N
22
Nuveen
North Carolina
$8.94M -$7.76M -399,937 -43%
Fidelity Investments
23
Fidelity Investments
Massachusetts
$8.49M +$35.6K +1,835 +0.4%
Goldman Sachs
24
Goldman Sachs
New York
$7.79M -$1.79M -92,007 -16%
MP
25
Mangrove Partners
Connecticut
$7.33M +$8.52M +439,314 New
1
2 3 4 5

PTGX Hedge Fund Activity: Q3 2023 in Review

144 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2023, worth a combined $946M — down 40% from $1.57B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of PTGX and 17 opened new positions — a net loss of 23 holders — while 40 trimmed existing stakes and 65 added.

The largest buyer was BVF Inc, adding an estimated $38.2M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $41.4M sold.

  • 144 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2023, down from 167 in Q2 2023.
  • Funds reported $946M of Protagonist Therapeutics stock for Q3 2023, down 40% quarter-over-quarter.
  • 17 funds opened new Protagonist Therapeutics positions in Q3 2023 and 40 closed out, a net change of -23 holders.
  • The largest Protagonist Therapeutics buyer in Q3 2023 was BVF Inc, an estimated $38.2M added.
  • The largest Protagonist Therapeutics seller in Q3 2023 was Cormorant Asset Management, an estimated $41.4M sold.

Based on aggregated 13F filings for Q3 2023.